9.24
price up icon0.00%   0.00
after-market 시간 외 거래: 9.24
loading
전일 마감가:
$9.24
열려 있는:
$9.24
하루 거래량:
454.80K
Relative Volume:
0.54
시가총액:
$657.62M
수익:
$133.62M
순이익/손실:
$-177.37M
주가수익비율:
-3.1972
EPS:
-2.89
순현금흐름:
$23.50M
1주 성능:
+3.01%
1개월 성능:
+7.94%
6개월 성능:
-52.98%
1년 성능:
-56.56%
1일 변동 폭
Value
$9.00
$9.36
1주일 범위
Value
$8.90
$9.69
52주 변동 폭
Value
$7.16
$27.24

Xencor Inc Stock (XNCR) Company Profile

Name
명칭
Xencor Inc
Name
전화
626-305-5900
Name
주소
465 N. HALSTEAD ST., PASADENA, CA
Name
직원
250
Name
트위터
Name
다음 수익 날짜
2024-11-05
Name
최신 SEC 제출 서류
Name
XNCR's Discussions on Twitter

XNCR을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
XNCR
Xencor Inc
9.24 657.62M 133.62M -177.37M 23.50M -2.89
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
469.65 121.28B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
563.10 60.96B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.81 42.77B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.99 36.21B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
291.47 32.08B 3.81B -644.79M -669.77M -6.24

Xencor Inc Stock (XNCR) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-04-21 개시 William Blair Outperform
2024-12-12 개시 Wells Fargo Overweight
2024-12-02 업그레이드 Piper Sandler Neutral → Overweight
2024-04-16 재확인 BTIG Research Buy
2024-02-28 다운그레이드 Piper Sandler Overweight → Neutral
2023-05-19 개시 BofA Securities Buy
2022-12-06 개시 Cowen Outperform
2022-10-13 업그레이드 Raymond James Outperform → Strong Buy
2022-09-21 개시 JP Morgan Overweight
2022-07-06 재개 Canaccord Genuity Buy
2022-02-11 개시 BMO Capital Markets Outperform
2022-01-21 개시 SMBC Nikko Outperform
2021-12-15 개시 H.C. Wainwright Buy
2021-10-15 재개 BTIG Research Buy
2021-02-24 업그레이드 Raymond James Mkt Perform → Outperform
2020-03-04 개시 Barclays Underweight
2020-02-25 업그레이드 Guggenheim Neutral → Buy
2020-01-30 개시 RBC Capital Mkts Outperform
2019-11-20 재개 Guggenheim Neutral
2019-08-07 다운그레이드 Guggenheim Buy → Neutral
2019-08-07 다운그레이드 Raymond James Outperform → Mkt Perform
2019-06-13 개시 Mizuho Buy
2019-04-12 개시 Guggenheim Buy
2019-03-27 개시 Berenberg Buy
2019-03-15 개시 Raymond James Outperform
2018-09-10 재개 BTIG Research Buy
2018-03-28 재개 Leerink Partners Outperform
2017-03-02 개시 Instinet Neutral
2017-03-02 재확인 Wedbush Outperform
2016-10-04 개시 Piper Jaffray Overweight
2015-12-22 개시 Canaccord Genuity Buy
2015-08-05 재확인 MLV & Co Buy
2015-02-12 재확인 Oppenheimer Outperform
2015-01-28 재확인 MLV & Co Buy
2014-07-11 개시 Oppenheimer Outperform
모두보기

Xencor Inc 주식(XNCR)의 최신 뉴스

pulisher
05:21 AM

Bank of New York Mellon Corp Reduces Holdings in Xencor, Inc. (NASDAQ:XNCR) - Defense World

05:21 AM
pulisher
Jul 25, 2025

Is Xencor Inc. a good long term investmentOver 200% growth - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

How Xencor Inc. stock performs during market volatilityDaily Top Gainers - Newser

Jul 25, 2025
pulisher
Jul 25, 2025

What drives Xencor Inc. stock priceAccelerated wealth building - Autocar Professional

Jul 25, 2025
pulisher
Jul 25, 2025

Xencor Inc. Stock Analysis and ForecastHigh-yield investments - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 23, 2025

What analysts say about Xencor Inc. stockUnmatched profit growth - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

Xencor, Inc. (NASDAQ:XNCR) Shares Sold by Arizona State Retirement System - Defense World

Jul 23, 2025
pulisher
Jul 22, 2025

Why Xencor Inc. stock attracts strong analyst attentionFree Access to Community - Newser

Jul 22, 2025
pulisher
Jul 21, 2025

Xencor, Inc. (NASDAQ:XNCR) Shares Sold by Teacher Retirement System of Texas - Defense World

Jul 21, 2025
pulisher
Jul 19, 2025

Where are the Opportunities in (XNCR) - news.stocktradersdaily.com

Jul 19, 2025
pulisher
Jul 19, 2025

What risks could impact Xencor Inc. stock performanceVerified Return Tips - Newser

Jul 19, 2025
pulisher
Jul 18, 2025

Xencor’s Phase 2 Study on Vudalimab in Prostate Cancer: Key Update and Market Impact - The Globe and Mail

Jul 18, 2025
pulisher
Jul 18, 2025

Principal Financial Group Inc. Grows Holdings in Xencor, Inc. (NASDAQ:XNCR) - Defense World

Jul 18, 2025
pulisher
Jul 16, 2025

[Latest] Global Ultomiris Drug Market Size/Share Worth USD 64.12 Billion by 2034 at a 31.52% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) - GlobeNewswire Inc.

Jul 16, 2025
pulisher
Jul 15, 2025

What makes Xencor Inc. stock price move sharplyLow Volatility High Yield Stocks - Newser

Jul 15, 2025
pulisher
Jul 03, 2025

Xencor, Inc. (NASDAQ:XNCR) Given Consensus Rating of “Moderate Buy” by Analysts - Defense World

Jul 03, 2025
pulisher
Jul 01, 2025

Fed. Circ. Won't Revisit Jepson Claim Ruling In Xencor IP Case - Law360

Jul 01, 2025
pulisher
Jun 28, 2025

(XNCR) Investment Analysis - news.stocktradersdaily.com

Jun 28, 2025
pulisher
Jun 18, 2025

Closing Figures Unveiled: Xencor Inc (XNCR) Drop -8.18, Closes at 8.31 - DWinneX

Jun 18, 2025
pulisher
Jun 18, 2025

Rhumbline Advisers Has $1.74 Million Stake in Xencor, Inc. (NASDAQ:XNCR) - Defense World

Jun 18, 2025
pulisher
Jun 18, 2025

Xencor (NASDAQ:XNCR) Shares Down 5.7% on Insider Selling - Defense World

Jun 18, 2025
pulisher
Jun 18, 2025

(XNCR) On The My Stocks Page - news.stocktradersdaily.com

Jun 18, 2025
pulisher
Jun 17, 2025

Xencor director Gustafson sells shares worth $27,595 - Investing.com Australia

Jun 17, 2025
pulisher
Jun 16, 2025

Xencor director Montgomery sells shares worth $20,422 - Investing.com

Jun 16, 2025

Xencor Inc (XNCR) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$23.40
price down icon 0.97%
$36.67
price up icon 0.22%
$103.95
price up icon 0.42%
$28.67
price up icon 3.99%
$115.31
price up icon 0.65%
biotechnology ONC
$291.47
price down icon 1.68%
자본화:     |  볼륨(24시간):